We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Integer (ITGR) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
The upcoming report from Integer (ITGR - Free Report) is expected to reveal quarterly earnings of $1.34 per share, indicating an increase of 20.7% compared to the year-ago period. Analysts forecast revenues of $412.05 million, representing an increase of 10.6% year over year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Integer metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts expect 'Revenue- Non-Medical' to come in at $13.88 million. The estimate suggests a change of -11.3% year over year.
It is projected by analysts that the 'Revenue- IMC - Advanced Surgical, Orthopedics & Portable Medical' will reach $25.74 million. The estimate indicates a change of -9.4% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenue- IMC - Cardio & Vascular' should arrive at $206.57 million. The estimate suggests a change of +11.2% year over year.
The collective assessment of analysts points to an estimated 'Revenue- IMC - Cardiac Rhythm Management & Neuromodulation' of $162.13 million. The estimate suggests a change of +13.6% year over year.
Shares of Integer have demonstrated returns of +2.3% over the past month compared to the Zacks S&P 500 composite's +5.8% change. With a Zacks Rank #2 (Buy), ITGR is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Integer (ITGR) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
The upcoming report from Integer (ITGR - Free Report) is expected to reveal quarterly earnings of $1.34 per share, indicating an increase of 20.7% compared to the year-ago period. Analysts forecast revenues of $412.05 million, representing an increase of 10.6% year over year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Integer metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts expect 'Revenue- Non-Medical' to come in at $13.88 million. The estimate suggests a change of -11.3% year over year.
It is projected by analysts that the 'Revenue- IMC - Advanced Surgical, Orthopedics & Portable Medical' will reach $25.74 million. The estimate indicates a change of -9.4% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenue- IMC - Cardio & Vascular' should arrive at $206.57 million. The estimate suggests a change of +11.2% year over year.
The collective assessment of analysts points to an estimated 'Revenue- IMC - Cardiac Rhythm Management & Neuromodulation' of $162.13 million. The estimate suggests a change of +13.6% year over year.
View all Key Company Metrics for Integer here>>>
Shares of Integer have demonstrated returns of +2.3% over the past month compared to the Zacks S&P 500 composite's +5.8% change. With a Zacks Rank #2 (Buy), ITGR is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>